A practical reference on angiotensin IV: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-15. Anything still debated is marked as such rather than presented as settled.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
==== Saline breast prosthesis ==== The first commercial model of a breast prosthesis filled with saline solution was made by Laboratoires Arion of France, which they publicly presented as a prosthetic medical device in 1964. The modern models of prosthetic breasts filled saline-solution are made with vulcanized shells composed of a silicone elastomer of great elasticity, like that of the skin and tissues of a woman's breast. In an augmentation mammoplasty to emplace a saline breast-prosthesis, the plastic surgeon employs a short incision to the chest wall, through that incision the surgeon then inserts the collapsed, empty prosthetic breast into the breast-implant socket, then fills the implanted breast prosthesis with saline solution. The surgeon then contours the implanted prosthetic breast for anatomical symmetry, and afterwards sutures shut the insertion incision. Functionally, the implantation of a saline breast-prosthesis yields good-to-excellent results of increased breast-size, a smoother contour for the breast hemisphere, and anatomic symmetry; however, such a breast augmentation might ripple and wrinkle the skin envelope of the breast, cosmetic defects that make noticeable the presence of the prosthetic breast to the eye and to the touch. Such cosmetic defects of the breast surgery usually occur among women with a small volume of adipose tissue in their breast hemispheres.
==== Tryptophan and 5-HTP ==== The amino acid tryptophan is converted into 5-hydroxytryptophan (5-HTP) which is subsequently converted into the neurotransmitter serotonin. Since serotonin deficiency has been recognized as a possible cause of depression, it has been suggested that consumption of tryptophan or 5-HTP may therefore improve depression symptoms by increasing the level of serotonin in the brain. 5-HTP and tryptophan are sold over the counter in North America, but requires a prescription in Europe. The use of 5-HTP instead of tryptophan bypasses the conversion of tryptophan into 5-HTP by the enzyme tryptophan hydroxylase, which is the rate-limiting step in the synthesis of serotonin, and 5-HTP easily crosses the blood–brain barrier unlike tryptophan, which requires a transporter. Small studies have been performed using 5-HTP and tryptophan as adjunctive therapy in addition to standard treatment for depression. While some studies had positive results, they were criticized for having methodological flaws, and a more recent study did not find sustained benefit from their use. The safety of these medications has not been well studied. Due to the lack of high quality studies, preliminary nature of studies showing effectiveness, the lack of adequate study on their safety, and reports of eosinophilia–myalgia syndrome from contaminated tryptophan in 1989 and 1990, the use of tryptophan and 5-HTP is not highly recommended or thought to be clinically useful.
The initial network of the Paris Métropolitain (soon commonly abbreviated to "Métro") was planned and built at one time in order to minimize disruption to the city from on-going construction and to open Line 1 and two branches in time for the Exposition Universelle in 1900. A design competition was held for the above-ground components, to alleviate the public's fear that they would mar the cityscape with an industrial appearance. The new entrances were stipulated to be "as elegant as possible but above all very light, prioritising iron, glass and ceramic". However, the submitted entries were all too bulky for many of the sidewalk sites. Adrien Bénard, the financier whose bank was underwriting the construction, liked the new Art Nouveau style and therefore instead persuaded the Compagnie du chemin de fer métropolitain de Paris (CMP) to appoint the still young Hector Guimard to design the entrances to the underground stations, while the elevated stations were designed by Jean-Camille Formigé, chief architect of the City of Paris. Rather than stone, Guimard used cast iron set in concrete both to reduce costs and to suit the sinuous Art Nouveau forms; they were painted in a green emulating weathered brass.
=== Europe === A marketing authorisation application for 68Ga-PSMA-11 (INN Gallium (68Ga) gozetotide), under the brand name Illucix, was made to the Danish Medicines Agency, on behalf of several EU countries and the UK. Approval is expected in 2022. In 2022 a marketing authorisation application was made by the manufacturer of 18F-DCFPyL (branded Pylclari) to the European Medicines Agency. Polish manufacturer and distributor of radiopharmaceutical procuts, Polatom, has been granted a US patent for a 99mTc-PSMA-T4 kit. In the UK, Tc-99m labelled PSMA has product authorisation but lacks funding.
Sources: en.wikipedia.org
Diagnosis of bone sarcomas begins with a thorough history and physical examination which may reveal characteristic signs and symptoms (see Signs and Symptoms above). Laboratory studies are not particularly useful in diagnosis, although some bone sarcomas (such as osteosarcoma) may be associated with elevated alkaline phosphatase levels, while others (such as Ewing sarcoma) can be associated with elevated erythrocyte sedimentation rate. Importantly, however, none of these laboratory findings are specific to bone sarcomas, meaning that elevations in these lab values are associated with many other conditions as well as sarcoma, and thus cannot be relied upon to conclusively diagnose sarcoma. Imaging studies are critically important in diagnosis, and most clinicians will order a plain radiograph (X-ray) initially. Other imaging studies commonly used in diagnosis include magnetic resonance imaging (MRI) studies and radioisotope bone scans. A CT scan is typically not used in diagnosis of most types of bone sarcoma, although it is an important tool for staging (see below). Definitive diagnosis requires biopsy of the tumor and careful review of the biopsy specimen by an experienced pathologist.
Further investigations showed that the babies had not been injected with the potassium via IV method, but instead, that they had received the injections in their backs and with clothes on while they were in the resuscitation room. On the same day that police announced the arrest of nurse Brenda Agüero, the minister of health of Córdoba, Diego Cardozo, resigned from his position after heavy criticism for his handling of the case. Cardozo said that he had presented his resignation with the goal of helping clarify and serve justice in the case. Governor Juan Schiaretti assigned the ministry to María Gabriela Barbás. In February 2023, the head of the hospital, 70-year-old Liliana Asís, was arrested and accused of concealing the unnatural deaths of the babies from the authorities. She was granted house arrest in May 2023 due to her deteriorating health while in prison. Along with Asís, more officials and local politicians were indicted for either concealment or wrongdoing.
In 1957, this total fell to five when one of the Liberal MPs died and the subsequent by-election was lost to the Labour Party, which selected the former Liberal Deputy Leader Megan Lloyd George as its own candidate. The Liberal Party seemed close to extinction. During this low period, it was often joked that Liberal MPs could hold meetings in the back of one taxi.
Alcohol dehydrogenase class-3 is an enzyme that in humans is encoded by the ADH5 gene. This gene encodes glutathione-dependent formaldehyde dehydrogenase or the class III alcohol dehydrogenase chi subunit, which is a member of the alcohol dehydrogenase family. Members of this family metabolize a wide variety of substrates, including ethanol, retinol, other aliphatic alcohols, hydroxysteroids, and lipid peroxidation products. Class III alcohol dehydrogenase is a homodimer composed of 2 chi subunits. It has virtually no activity for ethanol oxidation, but exhibits high activity for oxidation of long-chain primary alcohols and for oxidation of S-hydroxymethyl-glutathione, a spontaneous adduct between formaldehyde and glutathione. This enzyme is an important component of cellular metabolism for the elimination of formaldehyde, a potent irritant and sensitizing agent that causes lacrymation, rhinitis, pharyngitis, and contact dermatitis.
American history does not distinguish between civilians and military, not even women and children. They are the ones who used [a nuclear bomb] against Nagasaki. Can these bombs distinguish between infants and military? America does not have a religion that will prevent it from destroying all people. So we tell the Americans as people [...] that if they value their lives and the lives of their children, to find a nationalist government that will look after their interests and not the interests of the Jews. After 9/11, bin Laden maintained that women and children were not targeted in the attack—rather, symbols of America's "economic and military power." In December 2001, a video of bin Laden was released in which he did not admit responsibility for 9/11, but instead said:
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.